Company intelligence / Profile preview

Spot BioSystems

California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Spot BioSystems' lead candidate SPOT-mRNA01 targets skin aging and is in Phase 1. The company employs non-viral, exosome-based, high precision mRNA delivery, with applications in rare disease, cancer, ischemic injury, and age-associated protein replacement. Clinical data are not yet publicly available but one trial is ongoing as of August 2025.

Therapeutic areas: Dermatology
Modalities: mRNA-based drugsExosome-based therapy
Industry: Biotech

Drug pipeline

1 asset

SPOT-mRNA01

Partnerships

Beijing Sipo Biotechnology (for SPOT-mRNA01 program)

Beyond the preview

Go deeper on Spot BioSystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spot BioSystems.

Explore the full profile